## Pediatric Advisory Subcommittee of the Anti-Infective Drugs Advisory Committee

## Food and Drug Administration Center for Drug Evaluation and Research Hilton, The Ballrooms, 620 Perry Parkway, Gaithersburg, MD.

## Tracking Cancer Risk among Children with Atopic Dermatitis who are Treated with Topical Calcineurin Inhibitors

Draft Agenda for October 30, 2003

8:00	Call to Order, Introductions:	Joan P. Chesney, M.D., Chair
	Meeting Statement:	Thomas H. Perez, R.Ph., M.P.H. Executive Secretary
	Opening Comments:	Dianne Murphy, M.D. Director, Office of Counter- terrorism and Pediatric Drug Development and Jonathan Wilkin, M.D. Director, Division of Dermatologic and Dental Drug Products
8:30	Review of Topical Calcineurin Inhibitors	Bindi Nikhar, M.D. Division of Dermatologic and Dental Drug Pruducts
8:50	Topical Immunosuppressants (Calcineurin Inhibitors) - Animal Toxicology	Barbara Hill, Ph.D. Division of Dermatologic and Dental Drug Products
9:20	Post Marketing Adverse Event Reports	ODS Staff
9:30	Q&A for Presenters	
9:45	Break	
10:00	Studying the Risk of Cancer with Topical Calcineurin Inhibitor Use in Children: Design Issues	Lois La Grenade, M.D. Office of Drug Safety
10:50	Practical and Methodological Issues in Long Term Follow-up Studies	Elizabeth Andrews, Ph.D. RTI Health Solutions
11:20	The Role of Cancer Registries in Long Term Follow-up Studies	Phyllis Wingo, Ph.D. Centers for Disease Control Cancer Registry Program
11:50	Q&A for Presenters	
12:00	Lunch	
1:00	Open Public Hearing	
2:00	Discussion of Questions 1 & 2	
3:30	Wrap up and adjourn	